

# Year in Review 2019

## Auto inflammatory syndromes

### Basic science papers- by Hal Hoffman

#### New Monogenic Diseases

#### Immunodysregulation (immunodeficiency)

##### **Heterozygous Truncating Variants in POMP Escape Nonsense-Mediated Decay and Cause a Unique Immune Dysregulatory Syndrome.**

Poli, M. C., Ebstein, F., Nicholas, S. K., et al. S.; Am J Hum Genet. 2018 Jun 7;102(6):1126-1142. doi: 10.1016/j.ajhg.2018.04.010.

*Describes a novel interferonopathy with features of immunodeficiency*

##### **Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors.**

Giannelou A, Wang H, Zhou Q, et al. Ann Rheum Dis. 2018 Apr;77(4):612-619. doi: 10.1136/annrheumdis-2017-212401.

*Describes a new autoinflammatory disease with a novel mechanism of action involving RNA processing.*

#### Mechanism of Inflammasome mediated disorders

##### **Gasdermin D mediates the pathogenesis of neonatal-onset multisystem inflammatory disease in mice**

Xiao, J., Wang, C., Yao, J. Cet al. PLoS Biol. 2018 Nov 2;16(11):e3000047. doi: 10.1371/journal.pbio.3000047. eCollection 2018 Nov.; PMID 30388107.

##### **GSDMD is critical for autoinflammatory pathology in a mouse model of Familial Mediterranean Fever.**

Kanneganti A, Malireddi RKS, Saavedra PHV, et al. J Exp Med. 2018 Jun 4;215(6):1519-1529. doi: 10.1084/jem.20172060. PubMed PMID: 29793924; PubMed Central PMCID: PMC5987922.

*These 2 papers demonstrate that GSDMD plays an important role in mouse models of **inflammasomopathy***

##### **Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity**

Boucher D, Monteleone M, Coll RC et al. J Exp Med. 2018 Mar 5;215(3):827-840; PMID 29432122.

*This is the first potential molecular explanation for the self limited nature of many autoinflammatory diseases*

##### **Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome.**

Weiss ES, Girard-Guyonvarc'h C, Holzinger D, et al. Blood. 2018 Mar 29;131(13):1442-1455. doi: 10.1182/blood-2017-12-820852. PubMed PMID: 29326099; PubMed Central PMCID: PMC5877443

*This demonstrates the mechanistic and diagnostic role of IL-18 in MAS*

##### **TNF/TNFR axis promotes pyrin inflammasome activation and distinctly modulates pyrin inflammasomopathy.**

Sharma, D, Malik, A, Guy, C, Vogel, P, Kanneganti, T. D., Journal: J Clin Invest, 129: 1, 150-162, Epub Date: 2018/11/21, Date: Jan 2, PMC6307946, PMID 30457980.

*This elucidates the role of the TNF pathway in **pyrin inflammasomopathy** suggesting targeting TNF in FMF*

##### **Metabolic Induction of Trained Immunity through the Mevalonate Pathway.**

Bekkering, S., Arts, R. J. W., Novakovic, et al. Cell. 2018 Jan 11;172(1-2):135-146.e9. doi: 10.1016/j.cell.2017.11.025; PMID 29328908.

*Describes innate immune disease mechanisms of **mevalonate kinase deficiency***

#### Mechanism of interferon driven disorders

### **STING-associated vasculopathy develops independently of IRF3 in mice.**

Warner JD, Irizarry-Caro RA, Bennion BG, et al. J Exp Med. 2017 Nov 6;214(11):3279-3292., PMC5679177, PMID 28951494.

*Demonstrates a role for IFR3 pathway in mouse model of SAVI*

### **Cryo-EM structures of STING reveal its mechanism of activation by cyclic GMP–AMP**

Shang, G., Zhang, C., Chen, Z. J., et al.; eng; England; Nature. 2019 Mar;567(7748):389-393. doi: 10.1038/s41586-019-0998-5. Epub 2019 Mar 6.; PMID 30842659.

*Novel technology allows for visualization of molecular mechanism of STING function*

## **Novel Pre Clinical Therapies**

### **NLRP3**

**NLRP3 inflammasome inhibitor OLT1177 suppresses joint inflammation in murine models of acute arthritis.** Marchetti C, Swartzwelter B, Koenders MI, et al. Arthritis Res Ther. 2018 Aug 3;20(1):169. doi: 10.1186/s13075-018-1664-2.PMID:30075804

*Novel NLRP3 targeted therapy with potential for treating inflammasomopathies*

### **STING**

#### **Targeting STING with covalent small-molecule inhibitors.**

Haag SM, Gulen MF, Reymond L, et al. Nature. 2018 Jul;559(7713):269-273. doi: 10.1038/s41586-018-0287-8. Epub 2018 Jul 4.PMID: 29973723

*Description of novel STING inhibitors with translational potential*

## **Year in Review 2019- Auto inflammatory syndromes**

### **Clinical papers- by Joost Frenkel**

**Consensus proposal for taxonomy and definition of the autoinflammatory diseases (AIDs): a Delphi study.** Ben-Chetrit E, Gattorno M, Gul A, et al. Ann Rheum Dis 2018;77:1558-65

*A novel nomenclature for the autoinflammatory diseases primarily based on pathogenic mechanism*

**An International Delphi Survey for the Definition of New Classification Criteria for Familial Mediterranean Fever, Mevalonate Kinase Deficiency, TNF Receptor-associated Periodic Fever Syndromes, and Cryopyrin-associated Periodic Syndrome.** Federici S, Vanoni F, Ben-Chetrit E, et al. J Rheumatol 2019;46:429-36.

#### **Classification criteria for autoinflammatory recurrent fevers**

Gattorno M, Hofer M, Federici S, et al. Ann Rheum Dis 2019

*2 papers describing novel clinical and genetic classification criteria for the the major autoinflammatory diseases and the careful process by which these were established*

**Infantile Onset Intractable Inflammatory Bowel Disease Due to Novel Heterozygous Mutations in TNFAIP3 (A20).** Zheng C, Huang Y, Ye Z, et al. Inflamm Bowel Dis 2018;24:2613-20.

*Infantile onset IBD as a novel and severe presentation of A20 haploinsufficiency.*

**A Novel Cryopyrin-Associated Periodic Syndrome Caused by a Mutation in the Nucleotide-Binding Domain, Leucine-Rich Repeat Family, Pyrin Domain-Containing 3 (NLRP3) Gene.** Turunen JA, Wedenoja J, Repo P, et al. *Keratoendotheliitis Fugax Hereditaria: Am J Ophthalmol* 2018;188:41-50.  
*A completely novel presentation of NLRP3 mutations affecting the cornea*

**Gradual Symmetric Progression of DFNA34 Hearing Loss Caused by an NLRP3 Mutation and Cochlear Autoinflammation.** Nakanishi H, Kawashima Y, Kurima K, et al. *Otol Neurotol* 2018;39:e181-5.  
*A phenotype of CAPS predominantly or exclusively affecting the cochlea, responsive to IL-1 blockade.*

**Biallelic loss-of-function LACC1/FAMIN Mutations Presenting as Rheumatoid Factor-Negative Polyarticular Juvenile Idiopathic Arthritis.** Rabionet R, Remesal A, Mensa-Vilaro A, et al. *Sci Rep* 2019;9:4579,019-40874-2.  
*A novel phenotype of laccase deficiency: polyarticular JIA.*

**Familial Mediterranean Fever Is Commonly Diagnosed in Children in Israel with Periodic Fever Aphthous Stomatitis, Pharyngitis, and Adenitis Syndrome.** Butbul Aviel Y, Harel L, Abu Rumi M, et al. *J Pediatr* 2019;204:270-4.  
*A paper describing the overlap between PFAPA and FMF, incidentally proving the increased attack frequency of PFAPA upon glucocorticoid treatment.*

**Type I interferon-mediated autoinflammation due to DNase II deficiency.** Roderio MP, Tesser A, Bartok E, et al. *Nat Commun* 2017;8:2176,017-01932-3.  
*A novel interferonopathy due to DNase2 deficiency.*

**Novel proteasome assembly chaperone mutations in PSMG2/PAC2 cause the autoinflammatory interferonopathy CANDLE/PRAAS4.** de Jesus AA, Brehm A, VanTries R, et al. *J Allergy Clin Immunol* 2019;.   
*A novel proteasome associated autoinflammatory syndrome caused by deficiency of a chaperone protein.*

**Canakinumab for the Treatment of Autoinflammatory Recurrent Fever Syndromes.** De Benedetti F, Gattorno M, Anton J, et al. *N Engl J Med* 2018;378:1908-19.  
*Landmark paper describing the efficacy of canakinumab in **TRAPS**, **HIDS** and colchicine resistant **FMF**.*

**JAK1/2 inhibition with baricitinib in the treatment of autoinflammatory interferonopathies.** Sanchez GAM, Reinhardt A, Ramsey S, et al. *J Clin Invest* 2018;128:3041-52.  
*Elegant prospective study of JAK inhibition in **interferonopathies**.*

**The use of interleukin 1 receptor antagonist (anakinra) in Kawasaki disease: A retrospective cases series.** Kone-Paut I, Cimaz R, Herberg J, et al. *Autoimmun Rev* 2018;17:768-74.  
*Small retrospective case series of IL-1 blockade in Kawasaki, suggesting a favorable effect.*

**Successful therapy with secukinumab in a patient with generalized pustular psoriasis carrying homozygous IL36RN p.His32Arg mutation.** Gabeff R, Safar R, Leducq S, et al. *Int J Dermatol* 2019;58:e16-7.  
*Case report of favorable effect of secukinumab in **DITRA**.*

**Colchicine intoxication in familial Mediterranean fever patients using clarithromycin for the treatment of Helicobacter pylori: a series of six patients.** Haj Yahia S, Ben Zvi I, Livneh A. *Rheumatol Int* 2018;38:141-7.  
*Paper describing serious colchicine toxicity due to interaction with clarithromycin.*

**Use of colchicine in pregnancy: a systematic review and meta-analysis.**Indraratna PL, Virk S, Gurram D, Day RO. Rheumatology (Oxford) 2018;57:382-7.

*A systematic review confirming the **safety of colchicine in pregnancy**.*

**Clinical impact of a targeted next-generation sequencing gene panel for autoinflammation and vasculitis.**Omoyinmi E, Standing A, Keylock A, et al. PLoS One 2017;12:e0181874.

*A paper describing the yield of a large multigene autoinflammatory panel in clinical practice.*

**New workflow for classification of genetic variants' pathogenicity applied to hereditary recurrent fevers by the International Study Group for Systemic Autoinflammatory Diseases (INSAID).**Van Gijn ME, Ceccherini I, Shinar Y, et al J Med Genet 2018;55:530-7.

*A paper with great practical consequences for the determination of pathogenicity of variants in the autoinflammatory genes.*

**In silico validation of the Autoinflammatory Disease Damage Index.**Ter Haar NM, van Delft ALJ, Annink KV, et al. Ann Rheum Dis 2018;

*A paper confirming the feasibility and validity of measuring long term damage in autoinflammatory disease using the ADDI index.*